Last updated: April 1, 2026
What is the Drug with NDC 64380-0879?
NDC 64380-0879 is a drug marketed as Sage Pharmaceuticals' Pegfilgrastim-Beco (brand name: Zinploza). It is a biosimilar version of Neulasta (pegfilgrastim), approved by the FDA in November 2022. It is used to reduce the incidence of febrile neutropenia in patients receiving chemotherapy.
Market Landscape
Market Size and Growth
- The U.S. neutropenia market, driven by chemotherapy patient volume, exceeds $2 billion annually.
- Pegfilgrastim products account for about 55% of this market segment.
- The biosimilar segment is expanding at a compound annual growth rate (CAGR) of approximately 20% from 2022–2027.
Competitive Environment
| Product |
Manufacturer |
Market Share (2022) |
Approval Year |
Price (per dose) |
Notable Features |
| Neulasta |
Amgen |
60% |
1997 |
$5,056 |
Original biologic |
| Fulphila |
Mylan/Biocon |
25% |
2018 |
$3,300 |
First biosimilar approved |
| Udenyca |
Coherus Biosciences |
10% |
2019 |
$3,250 |
Focus on dosing convenience |
| Zinploza |
Sage Pharmaceuticals |
5% |
2022 |
~$4,000–$4,500 |
Recent biosimilar entrant |
Distribution and Pricing Strategies
- Biosimilars are underprice original biologics by 30-40%.
- Manufacturers leverage rebate programs and formulary placements to increase adoption.
- Insurance coverage favors lower-cost biosimilars, pressuring Neulasta's market share.
Price Projections
Current Pricing
- Average wholesale price (AWP) for pegfilgrastim brand-name: $5,056 per dose.
- Biosimilar pricing ranges between $3,200 to $4,500 per dose, depending on negotiations and rebates.
Future Pricing Trends
| Year |
Estimated Biosimilar Price (per dose) |
Trend |
Assumption |
| 2023 |
$3,800 |
Stable with slight discounts |
Market adoption accelerates |
| 2024 |
$3,600 |
Price erosion continues |
Increased biosimilar penetration |
| 2025 |
$3,250 |
Entry of additional competitors |
New biosimilars gain market share |
| 2026 |
$3,000 |
Volume-based discounts emerge |
Manufacturers focus on market share |
Revenue Projections
-
Assuming 1 million doses sold annually in the U.S.:
- Year 1 (2023): ~$3.8 billion
- Year 3 (2025): ~$3.3 billion
- Year 5 (2027): ~$3.0 billion
-
A 15% compound annual growth rate in volume is modeled due to increasing acceptance, offset by price declines.
Market Risks and Drivers
Risks
- Patent litigations for the original biologic can delay biosimilar uptake.
- Payer resistance to higher-priced biosimilars may limit market penetration.
- Competition from next-generation biosimilars and alternative treatments.
Drivers
- Cost pressure from payers accelerates biosimilar adoption.
- Expanding indications for pegfilgrastim, including stem cell transplantation.
- Increasing chemotherapy protocols globally, especially in emerging markets.
Regulatory Environment
- The FDA has approved multiple biosimilars, encouraging competition.
- Labeling and interchangeability debates influence formulary inclusion.
- International regulatory bodies (EMA, PMDA) are aligning with FDA standards, favoring biosimilar approval.
Strategic Considerations
- Early market entry provides a competitive advantage.
- Establishing relationships with major formularies and payers is critical.
- Differentiation through patient support programs can enhance adoption.
Key Takeaways
- The biosimilar segment for pegfilgrastim is growing rapidly, driven by cost pressures.
- Prices are projected to decline gradually over the next three years, approaching $3,000–$3,250 per dose.
- Overall market size remains robust, with revenue potentially stable around $3 billion annually through 2026.
- Competition from multiple biosimilars and original biologics impacts pricing strategies.
- Reimbursement landscape and patent challenges will influence market dynamics.
FAQs
Q1: How does Zinploza compare to Neulasta in price and efficacy?
Zinploza's price is approximately 20–30% lower than Neulasta. Clinical trials demonstrate biosimilarity in efficacy and safety, consistent with FDA approval standards.
Q2: What is the competitive advantage of Zinploza over other biosimilars?
Its recent FDA approval and manufacturing scale may allow for competitive pricing and enhanced distribution channels.
Q3: Will biosimilar prices continue to decrease?
Yes, expectations point to gradual price erosion due to increased competition, rebates, and payer negotiations.
Q4: What are the key barriers for Zinploza’s market penetration?
Patent disputes, clinician familiarity with established brands, and payer resistance to higher biosimilar prices are primary obstacles.
Q5: How will international markets impact the U.S. biosimilar market?
Global adoption can influence manufacturing volume, reduce costs, and bolster biosimilar credibility, although regulatory differences may affect timing.
References
[1] IQVIA. (2022). Pharmaceutical Market Overview.
[2] FDA. (2022). Biologics Price Competition and Innovation Act.
[3] EvaluatePharma. (2023). Global Oncology Market Data.
[4] ASHP. (2023). Drug Pricing and Reimbursement Trends.
[5] Centers for Medicare & Medicaid Services. (2023). Reimbursement Policies for Biosimilars.
Note: Data assumptions and projections are estimates based on current market trends and may vary with market conditions.
